Galectin Therapeutics Inc. is a leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins involved in progression or cause of disease. The promising role of galectin in cancer could give the company a distinct position with hopes of synergizing with other companies fighting cancer, from Dendreon Corporation to Generex Biotechnology Corporation.
Building a Promising Cancer Treatment Platform
Galectin Therapeutics is focused on the development of galectin protein inhibitors. With promising efficacy seen in clinical trials, the company is re-positioning its GM-CT-01 treatment to work in conjunction with existing cancer vaccines and other immune cancer therapies such as ipilimumab (Yevoy, BMS) to improve their efficacy. The new approach could transform it into a platform play targeting numerous indications.
Currently, more than 100 cancer vaccines are being developed by a variety of companies, both public and private, that trigger some part of the immune system to produce additional tumor infiltrating lymphocytes. Continue reading.